title: Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
authors.affiliation: Department of Internal Medicine I, Division of Oncology, Vienna University School of Medicine, Vienna, Austria.
authors.forename: R M
authors.initials: RM
authors.lastname: Mader
authors.forename: C
authors.initials: C
authors.lastname: Schrolnberger
authors.forename: B
authors.initials: B
authors.lastname: Rizovski
authors.forename: M
authors.initials: M
authors.lastname: Brunner
authors.forename: C
authors.initials: C
authors.lastname: Wenzel
authors.forename: G
authors.initials: G
authors.lastname: Locker
authors.forename: H G
authors.initials: HG
authors.lastname: Eichler
authors.forename: M
authors.initials: M
authors.lastname: Mueller
authors.forename: G G
authors.initials: GG
authors.lastname: Steger
mesh_terms: D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019075:Electrophoresis, Capillary; D005110:Extracellular Space / Q000378:metabolism; D005467:Floxuridine / Q000378:metabolism; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D011355:Prodrugs / Q000378:metabolism / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000556:secondary; D014018:Tissue Distribution
chemical_list: D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D005467:Floxuridine; D003841:Deoxycytidine; D000069287:Capecitabine; C418208:5'-deoxy-5-fluorocytidine; D005472:Fluorouracil; C025034:doxifluridine